Australien - Englisch - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ceftriaxone sodium, quantity: 298.3 mg (equivalent: ceftriaxone, qty 250 mg) - injection, powder for - excipient ingredients: - treatment of the following infections when caused by susceptible aerobic organisms. lower respiratory tract infections. caused by strep. pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph. aureus, h. influenzae, h. parainfluenzae, klebsiella sp. (including k. pneumoniae), e. coli, e. aerogenes, p. mirabilis and serratia marcescens. skin and skin structure infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, streptococcus group g, strep. pyogenes, strep. viridans, streptococcus sp. (excluding enterococci), peptostreptococcus sp., e. coli, e. cloacae, klebsiella sp . (including k. pneumoniae and k. oxytoca), p. mirabilis, m morganii and s. marcescens. urinary tract infections (complicated and uncomplicated). caused by e. coli, p. mirabilis, p. vulgaris, m morganii and klebsiella sp. (including k. pneumoniae). uncomplicated gonorrhoea (cervical/ urethral and rectal). caused by n. gonorrhoeae, including both pencillinase and nonpenicillinase producing strains. bacterial septicaemia. caused by strep. pneumoniae, e. coli and h. influenzae. bone infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, enterobacter sp., p. mirabilis and k. pneumoniae. joint infections. caused by methicillin sensitive staph. aureus, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, p. mirabilis, k. pneumoniae and enterobacter sp. meningitis. the initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by h. influenzae type b, n. meningitidis, strep. pneumoniae or enterobacteriaceae pending culture and sensitivity results. surgical prophylaxis. the preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. susceptibility testing. before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftriaxone sodium -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftriaxone sodium -

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

apotex corporation - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone for injection, usp appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused b

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

wockhardt limited - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone for injection, usp appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused b

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 10 g - before instituting treatment with ceftriaxone for injection usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by s

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 500 mg - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 500 mg - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lupin limited - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs, ceftriaxone for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by streptococcus pneumo

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

proficient rx lp - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs, ceftriaxone for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by streptococcus pneumo